Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD
Posted inDermatology news Oncology Transplantation

Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD

A multicenter study reveals significant discordance between clinician and patient assessments of skin cGVHD. While both correlate with survival, patient-reported outcomes are uniquely predictive of mortality in sclerotic disease, highlighting the need for integrated assessment models in clinical practice.
Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade
Posted innews Oncology Respiratory

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual checkpoint inhibition as a potent chemotherapy-free neoadjuvant alternative.
Beyond the Futility Threshold: Deferoxamine May Accelerate Recovery and Benefit Specific Subgroups in Intracerebral Hemorrhage
Posted inNeurology news Radiology

Beyond the Futility Threshold: Deferoxamine May Accelerate Recovery and Benefit Specific Subgroups in Intracerebral Hemorrhage

While the primary i-DEF trial results suggested futility for deferoxamine in unselected intracerebral hemorrhage patients, recent post hoc analyses reveal significant benefits in early neurological improvement, long-term recovery trajectories, and specific subgroups with moderate hematoma volumes.
Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial
Posted inInfectious Diseases news Respiratory

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial

The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression typical of linezolid, offering a promising alternative for drug-resistant TB therapy.
Synergistic Potential and Hematologic Hurdles: Sapacitabine and Olaparib in BRCA1/2-Mutated Metastatic Breast Cancer
Posted innews Oncology

Synergistic Potential and Hematologic Hurdles: Sapacitabine and Olaparib in BRCA1/2-Mutated Metastatic Breast Cancer

A Phase Ib study of sapacitabine and olaparib in gBRCA-mutated metastatic breast cancer showed a 50% objective response rate and 9.7-month median PFS. While significant hematological toxicities limited dose escalation, the combination demonstrated durable clinical benefit and provided key insights into resistance mechanisms.
Omadacycline Establishes Noninferiority to Moxifloxacin in Community-Acquired Bacterial Pneumonia: The OPTIC-2 Phase 3b Trial Results
Posted inInfectious Diseases news Respiratory

Omadacycline Establishes Noninferiority to Moxifloxacin in Community-Acquired Bacterial Pneumonia: The OPTIC-2 Phase 3b Trial Results

The OPTIC-2 phase 3b trial confirms that omadacycline is noninferior to moxifloxacin for treating community-acquired bacterial pneumonia (CABP). This once-daily aminomethylcycline offers a robust IV-to-oral monotherapy option with a favorable safety profile, particularly for patients with moderate-to-severe disease (PSI Class III/IV).